Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ASH 2014 | ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 1)

Name: ASH 2014: Phase II study of lenalidomide plus rituximab for mantle cell lymphoma (Part 1)
Uploaded: 2014-12-05T00:00:00Z
Duration: 4 min 38 s
Description: Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results.

Jia Ruan • 5 Dec 2014

ASH 2014

Lenalidomide

Dr Jia Ruan (Weill Cornell Medical College, New York, NY) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II study of the biologic doublet of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma, including the trial design, efficacy and safety endpoints, and results.